Human clinical trial of 'Covaxin' starts in Odisha

Published On 2020-07-28 04:30 GMT   |   Update On 2020-07-28 07:00 GMT
Advertisement

Bhubaneswar: The human clinical trial of India's first possible anti-Covid vaccine 'Covaxin' began at an institute here on Monday, an official said.

The human trial of the coronavirus vaccine has begun at the Institute of Medical Sciences and SUM Hospital in Bhubaneswar.

Covaxin has been administered to several volunteers, informed E.Venkat Rao, Principal Investigator of the trial process.

The volunteers went under a thorough screening procedure and several tests, he added.

SUM Hospital is one of the 12 centres selected by Indian Council of Medical Research (ICMR) for conducting phase one and two of the process.

Covaxin is being developed by Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV).

IMS and SUM Hospital is the only medical institute in Odisha which is conducting clinical trial of the vaccine.

Tags:    
Article Source : ians

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Disclaimer :- This story, apart from the heading, has not been edited by Medical Dialogues Team and is auto-generated from news agency feeds. Source: IANS

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News